Glenmark Pharmaceuticals Recalls Blood Pressure Medication Over Contamination Fears

A significant recall has been issued by Glenmark Pharmaceuticals Inc. for its blood pressure medication, Ziac, due to concerns over potential cross-contamination with another drug. More than 11,100 bottles of bisoprolol fumarate and hydrochlorothiazide tablets have been affected, as indicated in a notice from the Food and Drug Administration (FDA).

The recall stems from testing of reserve samples that revealed the presence of ezetimibe, a medication typically used to lower cholesterol levels. Ziac, which combines bisoprolol and hydrochlorothiazide, is prescribed to manage high blood pressure, allowing the heart to maintain a regular rhythm by blocking beta-1 receptors.

Details of the Recall

The recall, classified as Class III by the FDA, suggests that the likelihood of adverse health consequences from exposure to the affected products is minimal. The impacted pills are available in 2.5 mg and 6.25 mg doses. Specific packages subject to the recall include:

– 30-count bottles (NDC-68462-878-30)
– 100-count bottles (NDC-68462-878-01)
– 500-count bottles (NDC-68462-878-05)

The affected lot numbers have expiration dates ranging from November 2025 to May 2026. In total, 11,136 bottles have been recalled, raising concerns for patients relying on this medication for hypertension management.

The FDA has not yet provided guidance on what actions patients should take if they possess the affected medication. The Independent has reached out to both the FDA and Glenmark Pharmaceuticals for further clarification and comment.

As the situation develops, patients are advised to monitor updates from official health sources and consult with healthcare providers regarding their treatment options.